V800006
Sodium 1-decanesulfonate
suitable for HPLC, ≥99%
Synonym(s):
1-Decanesulfonic acid sodium salt
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
CH3(CH2)8CH2SO3Na
CAS Number:
Molecular Weight:
244.33
EC Number:
236-525-9
UNSPSC Code:
12352300
PubChem Substance ID:
Beilstein/REAXYS Number:
3918920
MDL number:
product line
Vetec™
assay
≥99%
technique(s)
HPLC: suitable
mp
>300 °C (lit.)
SMILES string
[Na+].CCCCCCCCCCS([O-])(=O)=O
InChI
1S/C10H22O3S.Na/c1-2-3-4-5-6-7-8-9-10-14(11,12)13;/h2-10H2,1H3,(H,11,12,13);/q;+1/p-1
InChI key
AIMUHNZKNFEZSN-UHFFFAOYSA-M
Application
Ion-associating reagent for HPLC, including analyses of peptides and proteins.
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Sodium 1-decanesulfonate
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mixtures of catanionic surfactants can be superspreaders: Comparison with trisiloxane superspreader.
N M Kovalchuk et al.
Journal of colloid and interface science, 459, 250-256 (2015-08-25)
Mixed solutions of cationic and anionic surfactants show considerable synergism in their wetting behaviour, but their spreading is affected considerably by the phase separation processes. The valuable information about wetting properties of synergetic mixtures can be obtained by using mixtures
Hongyan Yang et al.
ACS chemical neuroscience, 6(8), 1487-1501 (2015-07-15)
In vivo microdialysis is widely used to investigate how neurotransmitter levels in the brain respond to biologically relevant challenges. Here, we combined recent improvements in the temporal resolution of online sampling and analysis for serotonin with a brief high-K(+) stimulus
Luigi Battaglia et al.
Journal of pharmaceutical sciences, 103(7), 2157-2165 (2014-05-16)
The major obstacle to glioblastoma pharmacological therapy is the overcoming of the blood-brain barrier (BBB). In literature, several strategies have been proposed to overcome the BBB: in this experimental work, solid lipid nanoparticles (SLN), prepared according to fatty acid coacervation